Vimarsana
Biggest News Aggregation in the World

Page 39 - Biotechnology News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Biotechnology. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Biotechnology Today - Breaking & Trending Today

Bexion Pharmaceuticals, Inc. Announces Poster Presentation on BXQ-350 at the American Association for Cancer Research (AACR) Annual Meeting 2024 - Vimarsana News

Bexion Pharmaceuticals, Inc. Announces Poster Presentation on BXQ-350 at the American Association for Cancer Research (AACR) Annual Meeting 2024

/PRNewswire/ -- Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a novel class of biologic therapy to treat solid tumor...

Gabather Joins Forces with the Centre for Neuropsychiatric Schizophrenia Research in Denmark to Conduct a Clinical Phase II Study with GT-002 - Vimarsana News

Gabather Joins Forces with the Centre for Neuropsychiatric Schizophrenia Research in Denmark to Conduct a Clinical Phase II Study with GT-002

/PRNewswire/ -- Gabather AB (Nasdaq First North Growth Market: GABA) announces that the Company has signed a Collaborative Agreement with the Centre for...

Q.ANT presents new technology at Analytica in Munich - Vimarsana News

Q.ANT presents new technology at Analytica in Munich

Q.ANT is unveiling a compact particle sensor based on quantum technology at Analytica in Munich

BIO-TECHNE TO HOST CONFERENCE CALL ON MAY 1, 2024, TO ANNOUNCE THIRD QUARTER FISCAL 2024 FINANCIAL RESULTS - Vimarsana News

BIO-TECHNE TO HOST CONFERENCE CALL ON MAY 1, 2024, TO ANNOUNCE THIRD QUARTER FISCAL 2024 FINANCIAL RESULTS

/PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Wednesday, May 1, 2024, at...

Compugen Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potential of COM503 - Vimarsana News

Compugen Publishes Paper in Cancer Immunology Research Demonstrating Therapeutic Potential of COM503

/PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, today...